Sermorelin – Growth Hormone–Releasing Hormone (GHRH 1–29) Research Peptide
Compound Name: Sermorelin (GHRH 1–29)
Classification: Research Peptide – Growth Hormone–Releasing Hormone Fragment
Description:
Sermorelin is a synthetic research peptide consisting of the first 29 amino acids of the
endogenous growth hormone–releasing hormone (GHRH) sequence. In controlled laboratory
research environments, Sermorelin is widely studied for its role in peptide-mediated signaling
associated with the growth hormone axis and endocrine regulatory pathways.
Researchers commonly utilize Sermorelin in in-vitro and biochemical model systems to
examine receptor-binding dynamics, hypothalamic–pituitary signaling mechanisms, and
growth hormone–related regulatory processes. Due to its structural similarity to native
GHRH, Sermorelin serves as a valuable research tool for investigating peptide–receptor
interactions and endocrine signaling models.
This compound is supplied in lyophilized (freeze-dried) powder form to enhance
stability for controlled laboratory research applications.
References:
- Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H.
A potentially effective drug for patients with recurrent glioma: sermorelin.
Ann Transl Med. 2021;9(5):406.
PMID: 33842627 - Prakash A, Goa KL.
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic
growth hormone deficiency.
BioDrugs. 1999;12(2):139–157.
PMID: 18031173 - Neyzi O, Yordam N, Ocal G, et al.
Growth response to growth hormone–releasing hormone (1–29)-NH₂ compared with growth hormone.
Acta Paediatr Suppl. 1993;388:16–21.
PMID: 8329826
Disclaimer:
For Laboratory Research Use Only (RUO).
Not for human consumption. Not for therapeutic, diagnostic, or veterinary use.
